1. Introduction {#sec0005}
===============

The recent pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world has put aged people in front of a devastating horizon. As a matter of fact they make up around 30 % of all cases, 45−50% of all hospitalizations, and 80 % of all deaths ([@bib0005]; [@bib0080]; [@bib0105]). In these age strata SARS-CoV-2 disease (COVID-19) lethality rate can reach up to 50 % ([@bib0005]; [@bib0105]). This increased mortality may be explained in part by already known risk factors (frailty, infection acting as a trigger to decompensate other chronic conditions, immunosenescense, and development of geriatric syndromes\' cascade) ([@bib0160]); but in the actual world\'s alarm context, there are other evident or subtle reasons, like health-care systems collapse, lack of material and human resources, and disaster situations involving ethical issues, which are contributing to this poor results ([@bib0070]; [@bib0145]; [@bib0175]; [@bib0185]; [@bib0195]).

In addition, data about prognostic factors and accurate tools to predict COVID-19 patients\' outcomes are scarce ([@bib0215]). In a recent review, authors identified 10 prognostic indices, most of them poorly reported, at high risk of bias, and with suboptimal described performance ([@bib0220]). Having reliable prognostic tools is even more critical in the elderly, because their mortality is highest. In these populations it is our duty to avoid nihilism, offering best aggressive choices to those with good life expectancy; but also to avoid futility, offering best palliative care to those already in their end-of-life trajectory ([@bib0035]; [@bib0095]; [@bib0165]).

The significance of co-morbidities in the outcome of multiple acute diseases has largely been demonstrated ([@bib0075]; [@bib0090]; [@bib0100]; [@bib0170]). Nevertheless, in most initial series of COVID-19, the impact of underlying chronic conditions in morbidity and mortality has been only partially analyzed, whereas most focus had been put in acute symptoms and laboratory parameters ([@bib0105]). However, in a recent large multicenter cohort of patients with COVID-19, chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease and obesity were associated with higher in-hospital mortality ([@bib0065]). In this sense, there are already developed and contrasted prognostic tools centered on patients\' co-morbidities like the classic Charlson index, or the PROFUND index specifically developed for patients with multimorbidity and polypathology, which could be used to assess death-risk of elderly and vulnerable populations ([@bib0015]; [@bib0050]). In addition there are also simple and already contrasted tools to stratify death risk of patients with pneumonia, like CURB-65 ([@bib0110])

In the present work we have analyzed the predictive power of various prognostic tools specifically developed for COVID-19 in a multicenter cohort of elderly patients living in nursing homes and affected with COVID-19, and compared it to that of CURB-65 and two extensively used co-morbidity indices (Charlson and PROFUND), in order to know the best choice for death risk stratification in the attention to this vulnerable population.

2. Methods {#sec0010}
==========

This was a retrospective cohort study including all patients affected by COVID-19 from four nursing homes sizeable outbreaks, which occurred during March and April 2020 in the city of Seville, southern Spain.

2.1. Reference population and inclusion criteria {#sec0015}
------------------------------------------------

The total population of the 4 nursing homes was 457 residents (median age of 86 years-old \[Quartile1-Quartile3 (Q1-Q3) = 79--91\], 75 % women). All residents diagnosed with COVID-19 were included in the present study.

2.2. SARS-CoV-2 infection confirmation {#sec0020}
--------------------------------------

Universal SARS-CoV-2 testing to residents and staff members. Real-time polymerase chain reaction (RT-PCR) for the detection of specific viral ribonucleic acid (RNA) from nasopharyngeal swab-smears, and lateral flow serologic method from fingerstick blood samples for the detection of specific antibodies against SARS-CoV-2 were performed to confirm SARS-CoV-2 infection. For these purposes the Allplex® 2019-nCoV RT-PCR assay (Seegene Inc., Seoul, South Corea), for detection of gene targets ORF1ab and N; the VIASURE® SARS-CoV-2 RT-PCR assay (CerTest Biotec S.L., Zaragoza, Spain), for detection of gene targets RdRP, E and N; and the Wondfo® SARS-CoV-2 Antibody Test Lateral Flow Method assay (Guangzhou Wondfo Biotech Co Ltd, Guangzhou, China) for the detection of IgM and IgG antibodies, were implemented.

SARS-CoV-2 acute infection was defined when a compatible clinical syndrome plus either the detection of viral ribonucleic acid by RT-PCR (\'positive nasopharyngeal swab PCR\'), the presence of IgM or IgM and IgG antibodies (\'positive serology\'), or both, were documented.

2.3. Patients management, follow-up, and discharge {#sec0025}
--------------------------------------------------

A coordinated on-site medicalization program was quickly built to offer best clinical care to affected residents. All patients were attended following a common clinical management, treatment algorithm, hospital referral criteria, and were followed-up accordingly until recovery or death. Clinical recovery was defined after three days of being asymptomatic, and microbiological cure when the patient tested a control negative nasopharyngeal swab PCR after clinical cure. For the purposes of this study a 30-day period after SARS-CoV-2 infection confirmation was established.

2.4. Functional and death-risk indices {#sec0030}
--------------------------------------

The Barthel index was used to measure the fitness in activities of daily living ([@bib0130]). The assessment of co-morbidities global weight in determining death risk was analyzed with the Charlson and PROFUND indices ([@bib0015]; [@bib0050]). We selected CURB-65 score for the specific stratification of death risk in patients with pneumonia because of its demonstrated accuracy and easiness to use ([@bib0110]). Respecting newly developed scores specifically designed to assess death-risk of patients with COVID-19, we tested ACP and Shi et al. indices ([@bib0125]; [@bib0190]). Other recently developed scores could not be calculated because single dimensions\' weighing of scores\' variables were not available to use (Caramelo et al., COVID-19 vulnerability index, Surgisphere mortalitiy risk tool ([@bib0045]; [@bib0055]; [@bib0205])); the output of death-risk was individually established for every dimension, but with no global risk assessment (COVID-19 prognostic tool ([@bib0135])); dimensions were quantitatively accounted but the model equations were not available to use (([@bib0225])); or inclusion of computerized tomography (CT) image patterns were included [@bib0010]; [@bib0180]; [@bib0230], whereas CT was performed to none of our patients.

2.5. Data collection and variables {#sec0035}
----------------------------------

A complete set of demographical, clinical, functional, and pharmacological data were retrospectively collected from all included patients. Clinical data included the different diseases, and all possible co-morbidities, previous medications, functional parameters by means of Barthel\'s index, prognostic parameters by means of Charlson, PROFUND, CURB-65, ACP, and Shi et al. indices, different symptoms and signs, medical treatments, and outcome ([@bib0015]; [@bib0050]; [@bib0110]; [@bib0125]; [@bib0130]; [@bib0190]). These data were collected by clinicians in charge, who were active members of the investigation team.

The main outcome variable was survival. For this purpose, we looked at it as both a dichotomous and as time-dependent outcome. For the dichotomous outcome, subjects were categorized depending on whether or not they survived COVID-19 after the follow-up period. For the continuous outcome, survival time was defined as the number of days between the symptoms onset date (diagnosis date in those patients with asymptomatic infection) and the date of death.

2.6. Statistical analysis {#sec0040}
-------------------------

The dichotomous variables were described as whole integers and percentages, and the continuous variables as mean and standard deviation (or median and interquartile range in those with no criteria of normal distribution). The distribution of all variables was analyzed with the Kolmorogov-Smirnov test.

To assess the scores\' accuracy, we determined their calibration by comparing the predicted mortality obtained by logistic regression modeling (divided into their probability risk groups) to the observed mortality in the present cohort, and calculating the Hosmer-Lemeshow goodness-of-fit test (H-L) of the full range of scores, in combination with the calibration curve of every index; in addition, Kaplan-Meier curves were constructed in order to analyze mortality as a time-dependent outcome, in the separated risk strata of every index. Then, we evaluated the discrimination power of the scores by applying the respective point scoring to the present cohort, thereby determining risk scores for each patient, and calculating the area under the receiver operating characteristic curve (AUC-ROC). The AUC-ROC of all indices were compared, and the Youden index was calculated for every index, establishing afterwards the optimal cut-off value for the highest death-risk prognostication.

Finally, we calculated the sensitivity (S), specificity (E), negative, and positive predictive values (NPV and PPV) of the lowest and highest risk strata of every index and their combinations. For this purpose we assumed the development of the main event (death) as the absolute truth criterion 30 days after inclusion.

All parameters were quantified by calculating the 95 % confidence intervals. Statistic analysis was performed using the SPSS 22.0®, and Analyse-it® software.

2.7. Ethical and data quality issues {#sec0045}
------------------------------------

All patients or their legal representatives accepted the use of their anonymous clinical data for clinical research purposes. The study was approved by the by the local ethics committee (internal code: 1199-N-20). In this retrospective project the collection, process and analysis of all data was anonymously carried out, and only for the purposes of the project. All data were protected in accordance with the European Union directive 2016/679 of the European Parliament and the European Council, of April 27, 2016, regarding the protection of persons and their personal data. Missing data were replaced by single imputation techniques. In order to provide best quality and transparency of data description we followed STROBE and STARD recommendations and check-list ([@bib0040]; [@bib0210]).

3. Results {#sec0050}
==========

In total 272 residents affected with COVID-19 were included (59.5 % of the whole population). The main clinical features and different risk indices average scores are detailed in [Table 1](#tbl0005){ref-type="table"} . The cohort was composed mainly by elderly women, with multiple chronic conditions, vulnerability, and functional impairment. Most frequent symptoms were fatigue and global deterioration, low grade fever, dyspnea, and cough; and biological parameters alterations were similar to those already known to be associated to COVID-19. The scores of all indices were high, thereby determining a high death risk in the whole cohort of patients.Table 1Main clinical features of residents with COVID-19 during four nursing homes outbreaks in Seville, Spain.Table 1CLINICAL FEATURES OF THE 272 PATIENTSMEAN (SD)/MEDIAN \[Q1-Q3\] / Nº(%)Age and female gender87\[81−91\]; 205 (75.4%)Nº of comorbidities per patient4 \[3--6\]Most frequent comorbidities Hypertension198(73 %) Dyslipemia104 (38.2 %) Advanced dementia103 (37.8 %) Osteoarthritis76 (28 %) Depression72 (26.5 %) Diabetes mellitus71 (26 %) Mild-moderate dementia64 (23.5 %) NL disease with severe impairment59 (22 %) Cereborvascular disease53 (19.5 %) Atrial fibrillation52 (19 %) Chronic heart failure38 (14 %) Anxiety disorders37 (13.6 %) COPD or asthma36 (13 %) Coronary artery disease34 (12.5 %) Parkinson disease30 (11 %) Hypothyroidism24 (8.8 %)Nº of chronic prescribed drugs7.2 (3.6)Patients with symptoms206 (76 %)Most frequent symptoms Fatigue and global deterioration105 (38.6 %) Low grade fever (37−37.9 °C)98 (36 %) Dyspnea102 (37.5 %) Cough94 (34.6 %) Anorexia55 (20 %) Diarrhea52 (19 %) Delirium47 (17.3 %) High grade fever (≥38 °C)45 (16.55) Nausea/Vomiting17 (6.3 %) / 16 (5.9 %) Sneezing-runny nose10 (3.7 %) Fall(s)7 (2.6 %) Ageusia / Anosmia4 (1.5 %) / 3(1.1 %)Main biological parameters Hemoglobin (g/dL)11.7 (2.3) Lymphocytes (nº/μL)1262 (667) Platelets (nº/μL)249,000 (114,000) D dimer2231 (3932) Creatinin (mg/dL)1.34 (1.3) PCR70 (97) Ferritin (ng/mL)456 (646)Functional and death-risk indices Basal Barthel's Index49.5 (30) Charlson index1 \[1--4\] Charlson index adjusted by age6 \[5--7\] PROFUND index8.2 (4) CURB-652 \[1--3\] ACP index2 \[2--2\] Shi et al. index2\[2--2\]Number of hospitalized patients64 (23.5 %) Average hospital stay (days)12.5 \[9−15.5\]Mortality61 (22.4 %) Mortality in symptomatic / asymptomatic patients4 of 66 (6%) / 57 of 206 (27.7 %)[^1]

Overall mortality rate was 22.4 % (61 patients). A flowchart of the whole study is detailed in Supplementary Appendix, [Fig. 1](#fig0005){ref-type="fig"} . The calibration of all studied indices is detailed in [Table 2](#tbl0010){ref-type="table"} and in Supplementary Appendix, Figs. 2--7. Using H-L test all of them showed good calibration but CURB-65, whose calibration was poor. In the calibration curves, however, the highest calibration comparing predicted and observed mortality curves were obtained by PROFUND and ACP indices. Cumulative survival during follow-up according to risk groups of PROFUND and CURB-65 indices is detailed in [Fig. 1](#fig0005){ref-type="fig"}, in which significant differences in outcome trajectories according to risk strata, were obtained; when assessing this issue in the four remaining indices (Charlson index, Charlson index adjusted by age, ACP index, and Shi et al. index), no significant differences among their respective risk groups were obtained, but in ACP index (log rank test p = .01).Fig. 1Kaplan-Meier curve comparing survival of nursing homes\' residents affected by COVID-19, when stratified by PROFUND index (1.a) and CURB-65 index (1.b), respectively.Fig. 1Table 2Calibration of analyzed indices by comparison of their death-risk strata classification predictions, and observed mortality in a cohort of nursing home residents with COVID-19 in Seville, Spain.Table 2INDEXPREDICTED DEATH-RISK ORIGINALLY PUBLISHED BY AUTHORS (%)PREDICTED DEATH-RISK OBTAINED IN THE PRESENT COHORT (95% CI)\#OBSERVED MORTALITYHOSMER-LEMESHOV TEST: Chi square test (degrees of freedom)Charlson index2.19 (4) 0 points12 %21.5 %14 (22.6 %)p = .51 1−2 points26 %22 %23 (19.5 %) 3−4 points52 %23 %15 (28.3 %) 5 or more points85 %24.3 % (24−24.7%)9 (29.1 %)Charlson index adjusted by age1.85 (6) 0 points12 %\--0 (of no patients)p = .34 1−2 points26 %17.7 %0 of 5 patients 3−4 points52 %19.5 % (19.4−19.6%)12 (19.7 %) 5 or more points85 %23.4 % (23−23.8%)49 (23.8 %)PROFUND index9.72 (7) Low risk (0−2 points)12.1−14.6%8.3 % (8−8.7%)2 (7.4 %)p = .3 Low-intermediate risk (3−6 points)21.5−31.5%13.3 % (13−13.7%)10 (12.3 %) Intermediate-high risk (7−10 points)45−50%21.7 % (21.3−22%)17 (28 %) High risk (11−30 points)68−61.3%36 % (34.3−37%)32 (36.8 %)CURB-65 index18.62 (3) 0 points0.7 %2.6 %0 of 8 patientsp = .015 1 point1.3 %8%7 (5%) 2 points3%22.5 %23 (36.5 %) 3 points17 %49 %16 (40 %) 4 points41.5 %76 %12 (70.6 %) 5 points57 %91 %2 (100 %)ACP index.05 (1) Grade 1 (0 points)01.8%0 of 1patientp = .892 Grade 1 (1 points)5.6 %7.6 %5 (7.7 %) Grade 2 (2 points)33.2 %27 %56 (27.2 %)Shi et al index\*1.99 (1) 0 points0\--0 (of no patients)p = .275 1 point5.7 %17 %13 (21.3 %) 2 points19 %22.3 %30 (19.1 %) 3 points40 %28.6 %18 (33.3 %)[^2]

The discrimination power of all indices is detailed in [Fig. 2](#fig0010){ref-type="fig"} . The most discriminative tool was CURB-65 (AUC-ROC = 0.81\[0.75−0.87\]; p \< .001), followed by PROFUND Index (AUC-ROC = 0.67\[0.6−0.75\]; p \< .001); whereas the less discriminative tool was Charlson index (AUC-ROC = 0.53\[0.5−0.6\]; p = .4), and Charlson index adjusted by age ((AUC-ROC = 0.56\[0.48−0.64\]; p = .1). Differences among AUC-ROC curves of all indices are detailed in Supplementary Appendix Table S1. The decision threshold plots with the calculated Youden index are detailed in Supplementary appendix Fig. S8, and Table S2.Fig. 2Discrimination power of analyzed indices by comparison of their area under receiver operator curve in a cohort of nursing home residents with COVID-19 in Seville, Spain.ROC: receiver operator curve; AA: adjusted by age; Barthel: Barthel scale; PROFUND: PROFUND index; Charlson: Charlson index; ACP: ACP index; SHI: Shi el al. index; CURB65: CURB-65 index.Fig. 2

Assessment of S, E, NPV, and PPV of all indices is detailed in [Table 3](#tbl0015){ref-type="table"} . For this purpose, and in order to compare the lowest and highest death risk groups among all indices, we have only included the values of S, E, NPV and PPV corresponding to these lowest and highest risk groups. The highest S was obtained by lowest risk strata of PROFUND (97 % \[89−99%\], and its combination with that of CURB-65 (100 % \[94−100%\]); whereas highest risk strata of CURB-65 (98 % \[94−99%\]), and its combination with that of PROFUND (99 % \[97−99.7%\]) showed highest E. The highest NPV was obtained by lowest risk strata of CURB-65 (95 % \[90−98%\]), PROFUND (93 % \[77−98%\]), and their combination (100 % \[82−100%\]); whereas highest risk strata of CURB-65 (74 % \[51−88%\]), and its combination with that of PROFUND (80 % \[50−94%\]) showed highest PPV.Table 3Sensitivity (S), specificity (E), negative and positive predictive values (NPV and PPV) of the lowest and the highest risk strata of different prognostic indices in a cohort of nursing home residents with COVID-19 in Seville, Spain.Table 3Index and risk strataSensitivitySpecificityNPVPPVPROFUND 0−2 points97 % **(89−99%)**12 % (8.2−17%)93 % (77−98%)24 % (19−30%)PROFUND ≥11 points52 % (39−64%)74 % (68−79%)84 % (78−89%)36 % (27−47%)CURB-65 0−1 points88 % (78−94%)67 % (60−73%)95 % **(90−98%)**43 % (35−52%)CURB-65 ≥ 4 points23 % (14−35%)98 % **(94−99%)**82 % (76−86%)74 % **(51−88%)**Charlson 0 points77 % (65−86%)23 % (18−29%)77 % (66−86%)22 % (17−28.5%)Charlson ≥5 points15 % (8−26%)86 % (80−90%)78 % (72−83%)23 % (13−38%)AA Charlson 0−3 points\*94 % (86−98%)8% (5−12%)85 % (64−94%)23 % (18−28%)AA Charlson ≥5 points80 % (69−88%)26 % (20−32%)82 % (71−89%)24 % (18−30%)ACP 0−1 points\#96 % (90−99%)1% (0.1−3%)50 % (9−90%)25 % (22−34%)ACP = 3 points92 % (82−96%)29 % (23−35%)92 % (83−97%)27 % (21−33%)Shi et al.& ≥279 % (67−87%)23 % (17−29%)79 % (67−87%)23 % (17−29%)Shi et al. = 329 % (19−42%)83 % (77−87%)80 % (74−85%)33 % (22−47%)PROFUND 0−2 points and CURB-65 0−1 points100 % **(94−100%)**8.5 % (5.5−13%)100 % **(82−100%)**24 % (19−29%)PROFUND ≥11 points and CURB-65 ≥ 4 points13 % (7−24%)99 % **(97−99.7%)**80 % (74−84%)80 % **(50−94%)**[^3]

4. Discussion {#sec0055}
=============

After a thorough analysis, the most accurate indices to predict mortality of a nursing home elderly population of patients with COVID-19, were PROFUND and CURB-65. PROFUND index showed an excellent calibration and a good discrimination power, and CURB-65 index showed an acceptable calibration and an excellent discrimination power. In addition, both indices obtained high S and E values; and the combinations of their lowest and highest risk groups (patients with PROFUND score 0−2 and CURB-65 score 0−1; patients with PROFUND score ≥11 and CURB-65 score ≥4) obtained also the highest NPV (100 %) and PPV (80 %), respectively.

PROFUND index was originally developed and validated to predict 12-month mortality in hospital-based patients with multimorbidity, but its generalizability has been established later by means of historical, geographic, spectrum, and follow-up transportability (in primary care polypathological patients, in other geographical areas, in patients with heart failure, and in shorter (predicting hospitalization episode mortality) and longer (four years) periods of follow-up) ([@bib0025]; [@bib0030]; [@bib0060]; [@bib0120]; [@bib0150]). Recently a systematic revision of prognostic indices in patients with multimorbidity catalogued it as of satisfactory quality among other 35 evaluated tools ([@bib0200]). The different mortality risks among its strata, with respect those risks originally published are logical, because in the present study the end point was survival to the acute episode of COVID-19, whereas the original end point was 12-months survival; nevertheless in the present study we obtained a similar accuracy as that originally reported, and later validated in other populations ([@bib0015], [@bib0025]; [@bib0030]; [@bib0060]; [@bib0120]; [@bib0150]). Its main limitation may be the absence of any features due to the acute disease, which are important in predicting the short-term outcomes of all acute events. Based on the results of the present study (excellent calibration, significant differentiated trajectories among the four risk groups, and good discrimination power), PROFUND index could be an appropriate tool to assess the basal death risk due to chronic conditions, of frail elderly patients affected by COVID-19.

In present days, CURB-65 index is probably the most used prognostic tool in patients with pneumonia ([@bib0085]; [@bib0115]; [@bib0140]; [@bib0155]). Its accuracy in many different populations in addition with its easier and simpler calculation with respect to others, explain this fact ([@bib0085]; [@bib0115]; [@bib0140]; [@bib0155]). In the present study we obtained a similar accuracy as previously described ([@bib0085]; [@bib0115]; [@bib0140]; [@bib0155]). In previous reports, there has been some concern regarding its PPV ([@bib0115]); but in the present study, the highest risk group of CURB-65 and its combination with the same risk group of PROFUND index, showed a notably high PPV. In addition, an early and evident separation in its risk-strata trajectories in Kaplan-Meier curves was evident, conferring it therefore an early prediction power in mortality risk. Its main limitation may be the absence of any features regarding chronic conditions and global basal patient\'s status (functional, mental and sociofamiliar); in spite of the demonstrated important prognostic weight of these variables in elderly populations ([@bib0015]; [@bib0050]). Based on the results of the present study (acceptable calibration, significant differentiated trajectories among the four risk groups, and excellent discrimination power), CURB-65 index could be an appropriate tool to assess the current death risk of this population due to COVID-19 severity.

Charlson index obtained poor results, even using its version adjusted by age. We have also detected this fact in comparisons performed with other current indices ([@bib0015], [@bib0020]). We are aware and agree about its historical value (it was pioneer, and could be considered even legendary), but nowadays we have serious concerns regarding its precision (calibration and discrimination power). The index only considers chronic diseases, but not other important parameters like functional measures or geriatric associated conditions. As a matter of fact, according to its dimensions\' relative weights, Charlson index systematically overestimate death risk.

With respect to the recent indices specifically developed for COVID-19, finally we could analyze only two of them, because of different reasons. In some of them the weights of their dimensions were not available, other did not put out the global death risk, and some of them included dimensions, which are not routinely performed in these population (like CT scans) ([@bib0010]; [@bib0045]; [@bib0055]; [@bib0135]; [@bib0180]; [@bib0205]; [@bib0225]; [@bib0230]). In addition most of them are not yet published after peer review ([@bib0010]; [@bib0045]; [@bib0055]; [@bib0125]; [@bib0135]; [@bib0180]; [@bib0190]; [@bib0205]; [@bib0225]). ACP index includes only age and C-reactive protein, and Shi et al. index only age, sex and hypertension as predictors; these variable packages showed being insufficient to predict mortality in a frail aged population with multimorbidity, in which other important aspects should be accounted. This is the most plausible explanation for the lack of precision of these indices with respect to that of PROFUND and CURB-65, which do take into account these important aspects in aging populations.

COVID-19 affects more frequently and severely elderly people. On the other hand, basal status of chronic conditions and clinical syndromes due to aging process are important issues to consider in the care planning of this population. For these reasons appropriately stratifying with the aid of accurate tools has to be a cornerstone in the clinical care of elderly patients with COVID-19. Taking into account the results of the present study, we suggest this stratification to be performed on two axis detailed in [Fig. 3](#fig0015){ref-type="fig"} . The first dimension to assess should be the death risk due to basal status and severity of chronic conditions, by means of PROFUND index; with this assessment we could differentiate those patients with good life expectancy in which a nihilist practice should be avoided and an etiopathogenic approach is the best choice; and those patients with basal severe illnesses or already in their end-of-life trajectory, in which futility and iatrogenia should be avoided and a more symptomatic approach is the best clinical practice. The second axis to evaluate is the current death risk due to the severity of COVID-19, by means of CURB-65 index; standard care should be offered to patients with mild-moderate disease, while an intensified care with advanced measures (intensive care for those with good life expectancy and advanced palliative care for those who are already in their end-of-life process) is the best option.Fig. 3Proposed comprehensive approach to elderly patients with COVID-19, based on a two-level risk stratification using PROFUND and CURB-65 indices.Fig. 3

This study has some limitations, that should be remarked. The results could be limited by the number of patients, but on the other hand the cohort was homogeneous and probably represents adequately nursing homes\' populations. Additionally, the retrospective collection of the cohort\'s data, could introduce some errors or biases, but for the purpose of the present study, this issue may be of less significance (deaths as end-point are difficult to get unnoticed, and all the remaining variables are normally available in most patients). Finally, only two recently developed COVID-19 prognostic scores could be compared with the other chosen tools due to the lack of required information needed for the specified data analysis.

In conclusion, the combination of PROFUND and CURB-65 indices showed the highest accuracy in predicting death-risk of elderly patients living in nursing-homes and affected by COVID-19, whereas Charlson index and recent developed COVID-19 specific tools lacked it, or were not available to assess. A comprehensive clinical approach stratifying these patients on a two-level basis (basal death risk due to chronic conditions by PROFUND index, plus current death risk due to COVID-19 by CURB-65), could be appropriate.
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[^1]: SD = standard deviation; Q1-Q3=quartile1-quartile3; Nº=number; %=percentage; NL neurological; COPD chronic obstructive pulmonary disease.

[^2]: CI: Confidence Interval; \#Obtained by logistic regression modeling; ¶These indices assess 12-month death risk; \*This index assesses risk to develop severe cases.

[^3]: AA: Adjusted by age; \*There were no patients with a score ranging of 0−1 points and only 5 patients with 2 points; \#There was only one patient with 0 points in the score; &There were no patients with 0 points in the score.
